Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Oridis Licenses Tissue Microarray Technology

By Labmedica staff writers
Posted on 05 Dec 2006
Oridis Biomed (Graz, Austria), a biopharmaceutical company, announced that it has entered into a license agreement with the National Institutes of Health (NIH, Bethesda, MD, USA) for the worldwide commercial use of NIH's proprietary tissue microarray (TMA).

TMAs are a tool within Oridis Biomed's Tissomics platform, which permits the rapid and simultaneous study of several hundred tissue samples, using standardized high-throughput analysis by in-house pathologists.

"We are pleased to have been granted by the NIH a license for this TMA technology”, said Georg Casari, Ph.D., head of Oridis Biomed's Tissomics business. More...
"This license agreement further strengthens our Tissomics business for the life-science industry worldwide, where we offer our clients the ability to validate their research, such as biomarker and target verification programs.”

Oridis Biomed commercializes its proprietary Tissomics platform in collaboration with industrial partners, as well as its own research and development programs. The company is developing diagnostics, biomarkers (targeted treatment solutions), and therapeutics for liver diseases. Therapeutic programs include primary liver cancer (hepatocellular carcinoma, HCC) and metabolic liver diseases, such as alcoholic steatohepatitis (ASH) and non- alcoholic steatohepatitis (NASH), where incidence rates are rapidly increasing, while treatment options are limited, expensive, and often ineffective.



Related Links:
Oridis Biomed
National Institutes of Health

Gold Member
Collection and Transport System
PurSafe Plus®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
Automatic CLIA Analyzer
Shine i9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.